RAY SINSON
BD and Supply Chain
Overview:
Ray Sison is a seasoned pharmaceutical consultant with over [X] years of experience in the industry. With an extensive background in regulatory affairs, clinical trials, and healthcare compliance, Ray brings a wealth of knowledge and a proven track record of helping pharmaceutical companies navigate complex industry challenges. Ray’s expertise covers both national and international standards, making him a valuable partner for companies looking to ensure safety, efficacy, and compliance in their products.
Therapy Details and Mechanism
NeuroGen-X is a gene therapy designed to target the root cause of the neurodegenerative condition, which involves mutations in a specific gene responsible for neural functioning. By introducing a healthy copy of the gene into affected cells, NeuroGen-X aims to restore proper cell function, slow down disease progression, and reduce symptoms.
How NeuroGen-X Works:
•Gene Targeting: Delivers a healthy gene copy directly to neurons affected by the mutation.
•Neuroprotection: Helps protect neurons from further damage, potentially delaying disease progression.
•Symptom Management: Reduces symptoms, improving patient mobility, coordination, and cognitive function.
Clinical Trials have shown that patients treated with NeuroGen-X experienced a 40% improvement in symptoms within the first six months, with many patients reporting sustained benefits.
